Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 1997

View Archived Issues

NIH seeks licensees for antispasmodic immunotoxin

Licenses offered for vasospasm therapy

NIH seeks licensees for method of treating allergies and HIV

Method of treating allergies and HIV offered for licensing

NIH seeks licensees for therapeutic/diagnostic HAV receptor

Antiviral nucleoside analogues available for licensing

CD40 ligands and MAbs offered for licensing

NIH seeks licensees for cancer vaccines

Licensees sought for recombinant laminin receptors

Transcriptional cofactor offered by NIH

DNA sequencing technology available for licensing

Medco's cardiovascular evaluation agent receives European approval

Correlation between asthma and IL-10

Gene vaccination shows potential against allergy

Phase I results with rhIL-4 receptor

Long-term use of recombinant IFN-gamma evaluated

Acorda and Elan to collaborate on spinal cord injury treatment

GalaGen's Diffistat-G advances through phase I

Role of IL-5 in asthma

IL-15 enhancement of neonatal defenses

Merck's Fosamax earns recommendation

Combination beta-agonist/corticosteroid therapy beneficial in asthma

Novo Nordisk's growth hormone now available in 67 countries

Efficacy of hydoxychloroquine in asthma

Review date set for Sonus ultrasound contrast agent

CytoTherapeutics and Cognetix collaborate on CNS R&D

Provir progresses through clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...